
BioMarin Pharmaceutical Inc.
BMRNAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Nov 3, 2026 | Oppenheimer | Leland Gershell | $94.00(+64%) | $57.44 | StreetInsider |
| Nov 3, 2026 | Stifel Nicolaus | Paul Matteis | $66.00(+15%) | $57.44 | StreetInsider |
| Oct 21, 2026 | Morgan Stanley | $122.00(+116%) | $56.48 | TheFly | |
| Oct 14, 2026 | Barclays | $114.00(+110%) | $54.38 | TheFly | |
| Sep 15, 2026 | BMO Capital | $97.00(+50%) | $64.60 | TheFly | |
| Sep 1, 2026 | Cantor Fitzgerald | $86.00(+32%) | $65.31 | TheFly | |
| Sep 1, 2026 | Piper Sandler | $90.00(+38%) | $65.23 | TheFly | |
| Aug 31, 2026 | Jefferies | Akash Tewari | $105.00(+60%) | $65.53 | TheFly |
| Aug 31, 2026 | Raymond James | $109.00(+67%) | $65.39 | TheFly | |
| Aug 26, 2026 | UBS | $88.00(+33%) | $66.10 | StreetInsider | |
| Aug 18, 2026 | BMO Capital | David Lebowitz | $98.00(+46%) | $66.99 | TheFly |
| Aug 18, 2026 | H.C. Wainwright | $59.00(-13%) | $67.79 | TheFly | |
| Aug 17, 2026 | Piper Sandler | $88.00(+31%) | $67.36 | TheFly | |
| Aug 17, 2026 | Barclays | Eliana Merle | $111.00(+65%) | $67.36 | TheFly |
| Aug 10, 2026 | Canaccord Genuity | Whitney Ijem | $114.00(+79%) | $63.81 | StreetInsider |
| Aug 7, 2026 | Raymond James | $105.00(+65%) | $63.80 | TheFly | |
| Aug 7, 2026 | Morgan Stanley | $124.00(+94%) | $63.84 | TheFly | |
| Aug 7, 2026 | Stifel Nicolaus | $70.00(+10%) | $63.55 | TheFly | |
| Aug 7, 2026 | Oppenheimer | Leland Gershell | $97.00(+58%) | $61.46 | StreetInsider |
| Jul 7, 2026 | RBC Capital | Luca Issi | $62.00(+5%) | $58.79 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| JP Morgan | maintain | Overweight | Nov 4, 2026 |
| Stifel | maintain | Hold | Nov 3, 2026 |
| Morgan Stanley | maintain | Overweight | Nov 3, 2026 |
| Oppenheimer | maintain | Outperform | Nov 3, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Nov 3, 2026 |
| RBC Capital | maintain | Sector Perform | Nov 3, 2026 |
| Morgan Stanley | maintain | Overweight | Oct 21, 2026 |
| JP Morgan | maintain | Overweight | Oct 20, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Oct 20, 2026 |
| Barclays | maintain | Overweight | Oct 14, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Sep 10, 2026 |
| Piper Sandler | maintain | Overweight | Sep 1, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Aug 31, 2026 |
| Jefferies | maintain | Buy | Aug 31, 2026 |
| BMO Capital | maintain | Outperform | Aug 19, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Aug 18, 2026 |
| Barclays | maintain | Overweight | Aug 17, 2026 |
| Piper Sandler | maintain | Overweight | Aug 17, 2026 |
| Canaccord Genuity | maintain | Buy | Aug 10, 2026 |
| HC Wainwright & Co. | maintain | Neutral | Aug 7, 2026 |
| Morgan Stanley | maintain | Overweight | Aug 7, 2026 |
| Oppenheimer | maintain | Outperform | Aug 7, 2026 |
| Citigroup | maintain | Buy | Jul 16, 2026 |
| RBC Capital | maintain | Sector Perform | Jul 7, 2026 |
| Canaccord Genuity | maintain | Buy | May 22, 2026 |
Earnings History
Next report: Feb 22, 2027 · EPS est. $0.82| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 2, 2026 | $0.23 | $-0.05 | $1.02B | $1.02B |
| Aug 6, 2026 | $1.20 | $0.95 | $989.7M | $932.0M |
| May 4, 2026 | $0.76 | $0.78 | $766.0M | $752.5M |
| Feb 23, 2026 | $-0.24 | $0.17 | $874.6M | $833.7M |
| Oct 27, 2025 | $-0.16 | $-0.15 | $776.1M | $777.5M |
| Aug 4, 2025 | $1.23 | $0.86 | $825.0M | $761.9M |
| May 1, 2025 | $0.97 | $0.71 | $745.1M | $738.7M |
| Feb 19, 2025 | $0.64 | $0.54 | $747.0M | $712.3M |
News
Bfsg LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 17,538 shares of the biotechnology company's stock, valued at approximately $1,052,000. Other hedge funds and other institutional investors also recently added to
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,961 call options on the stock. This is an increase of approximately 228% compared to the typical daily volume of 1,206 call options. BioMarin Pharmaceutical News Summary Here are the key news stories impacting
BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.
Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.
BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Brian Mueller - CFO & Executive VP of Finance Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Eliana Merle - Barclays Bank PLC, Research Division Adit…
BioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic conditions business grew 44%.
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (H…
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $58.44 and traded as high as $59.37. BioMarin Pharmaceutical shares last traded at $58.51, with a volume of 2,273,689 shares. Analyst Ratings Changes Several equities research analysts
Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront payment of $70 million; GC and Hanmi will be jointly eligible to receive additional payments upon certain development and commercial milestones, and tiered royalties on net sales of HM15421/GC1134A SAN RAFAEL, Calif., Oct. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today an…
SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m.
Quadrant Capital Group LLC bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) during the undefined quarter, according to its most recent filing with the SEC. The fund bought 9,402 shares of the biotechnology company's stock, valued at approximately $564,000. Several other institutional investors have also made changes to their
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,339,560 shares of the biotechnology company's stock after selling 422,526 shares during
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Analyst Recommendations This is a summary of recent
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypoch…
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D.